Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine

Autor: Gisolf, E. H., Dreezen, C., Danner, S. A., Weel, J. L.F., Weverling, G. J., Reiss, P., Duurvoort, M., Krijger, E., Brouwer, E., Visser, G. R., Klotz, A., Benschop, C., Wulfert, F., Wolf, F. De, Jurriaans, S., Portegies, P., Colebunders, R., Pelgrom, J., Wijnants, H., DE Roo, A., Keersmaekers, K., Vandenbruane, M., Branden, D. Van Den, James, T., Wanzeele, F. Van, Gucht, B. Van Der, Van Der Ende, M. E., Nouwen, J., Deenenkamp, R., Van Der Meyden, D., Koopmans, P. P., Brinkman, K., Ver Hofstede, H., Zomer, B., Blok, W. L., Ruissen, C., Sprenger, H., Law, G., Meulen, P. Vander, Veen, C. Ten, Juttmann, J. R., Heul, C. Vander, Santegoets, R., Ven, B. Vander, Kate, R. W.Ten, Schoemaker, M., Kauffmann, R. H., Henrichs, J. M., Maat, A., Prins, E., Napel, C. H.H.Ten, Pogany, K., Duyts, T., Simons, P., Lacor, P., Waele, A. De, Wijngaarden, E. Van, Lejeune, M., Nieuwkerk, P., Sprangers, M., Roos, M., Scholte, R., Dijkman, J., Japour, A. J., Borst, M. J., Leeuwen, E. Van

Publikováno v: Clinical Infectious Diseases, 31(5), 1234-1239. Oxford University Press
Clinical Infectious Diseases, 31(5), 1234-1239
Gisolf, E H, Dreezen, C, Danner, S A, Weel, J L F, Weverling, G J, Reiss, P, Weverling, G J, Duurvoort, M, Krijger, E, Brouwer, E, Visser, G R, Klotz, A, Benschop, C, Wulfert, F, Danner, S A, Wolf, F D, Jurriaans, S, Portegies, P, Colebunders, R, Pelgrom, J, Wijnants, H, DE Roo, A, Keersmaekers, K, Vandenbruane, M, Branden, D V D, James, T, Wanzeele, F V, Gucht, B V D, Van Der Ende, M E, Nouwen, J, Deenenkamp, R, Van Der Meyden, D, Koopmans, P P, Brinkman, K, Ver Hofstede, H, Zomer, B, Blok, W L, Ruissen, C, Sprenger, H, Law, G, Meulen, P V, Veen, C T, Juttmann, J R, Heul, C V, Santegoets, R, Ven, B V, Kate, R W T, Schoemaker, M, Kauffmann, R H, Henrichs, J M, Maat, A, Prins, E, Napel, C H H T, Pogany, K, Duyts, T, Simons, P, Lacor, P, Waele, A D, Wijngaarden, E V, Lejeune, M, Wijngaarden, E V, Lejeune, M, Nieuwkerk, P, Sprangers, M, Roos, M, Scholte, R, Dijkman, J, Japour, A J, Borst, M J & Leeuwen, E V 2000, ' Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine ', Clinical Infectious Diseases, vol. 31, no. 5, pp. 1234-1239 . https://doi.org/10.1086/317449
Clinical infectious diseases, 31, 1234-1239. Oxford University Press

Liver enzyme elevation (LEE) is commonly observed after combination antiretroviral therapy (ARVT) for HIV infection is begun. Potential risk factors for LEE after treatment with ritonavir and saquinavir with or without stavudine were investigated in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f615f6536c6a96e7085c25f5eb7ec42c
https://pure.eur.nl/en/publications/beadb3d0-5a2a-44c7-85c9-eaddd275ab6c

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.